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Abstract 
To avoid pathological platelet aggregation by von Willebrand factor (VWF), VWF multimers 
are regulated in size and reactivity for adhesion by ADAMTS13-mediated proteolysis in a 
shear flow dependent manner. We examined if tensile stress in VWF under shear flow 
activates the VWF A2 domain for cleavage by ADAMTS13 using molecular dynamics 
simulations. We indeed observed stepwise unfolding of A2 and exposure of its deeply buried 
ADAMTS13 cleavage site. Interestingly, disulfide bonds in the adjacent and highly 
homologous VWF A1 and A3 domains obstruct their mechanical unfolding. We generated a 
full length mutant VWF featuring a homologous disulfide bond in A2 (N1493C and C1670S), 
in an attempt to lock A2 against unfolding. We find this mutant to feature ADAMTS13-
resistant behavior in vitro. Our results yield molecular-detail evidence for the force-sensoring 
function of VWF A2, by revealing how tension in VWF due to shear flow selectively exposes 
the A2 proteolysis site to ADAMTS13 for cleavage while keeping the folded remainder of A2 
intact and functional. We find the unconventional ‘knotted’ Rossman fold of A2 to be the key 
to this mechanical response, tailored for regulating VWF size and activity. Based on our 
model we can explain the pathomechanism of some natural mutations in the VWF A2 domain 
that significantly increase the cleavage by ADAMTS13 without shearing or chemical 
denaturation, and provide with the cleavage-activated A2 conformation a structural basis for 
the design of inhibitors for VWF type 2 diseases. 
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Introduction 
Von Willebrand factor (VWF) is a huge multimeric protein found in blood plasma. VWF 
mediates the adhesion of platelets to the sub-endothelial connective tissue and is the key 
protein in primary hemostasis in arterial vessels and the microcirculation (1, 2). Monomeric 
VWF is synthesized solely in megakaryocytes and endothelial cells. After transfer from the 
cytosol to the endoplasmatic reticulum, dimers form by C terminal disulfide bonds between 
CK domains (cf. Fig. 1A). Multimers consisting of up to 100 VWF monomers are then 
formed in the Golgi and post-Golgi compartment by cystin formation between the N terminal 
D3 domains. VWF is highly glycosylated, oligosaccharides make up about 20% of the mass 
of VWF (3). The multimers are either constitutively secreted or stored in endothelial Weibel-
Palade bodies and platelet α-granules and released from these storage organelles by adequate 
stimuli. The VWF multimers released from storage are particularly rich in ultra-large VWF 
(ULVWF). These highly active forms get rapidly yet only partially cleaved by the protease 
ADAMTS13 at the cleavage site Tyr1605—Met1606 within the A2 domain (4, 5). 
ADAMTS13 is a zinc containing metallo-protease from the ADAMS/ADAMTS family. Shear 
stress in blood vessels has been shown to drive VWF multimers into an elongated 
conformation with increased activity for adsorption to the blood vessel surface, a mechanism 
to stop bleeding after mechanical injury (6, 7). Mechanical forces due to shear flow regulate 
selective cleavage of ULVWF and thereby their size distribution (8, 9). If this size regulation 
fails, ULVWF accumulates and results in phenotypic manifestation of thrombotic 
thrombocytopenic purpura (TTP) (10). In contrast, reduced VWF concentration or complete 
absence of VWF results in the different types of von Willebrand disease (VWD) (11), the 
most common inherited bleeding disorder in humans. While the shear stress induced adhesion 
and cleavage have been demonstrated in detail in vitro, the underlying molecular mechanism 
of shear induced activation of VWF for ADAMTS13 cleavage is currently unknown. 
Structural information at atomic detail on the VWF is scarce. A single VWF is a multi-
domain protein featuring a multitude of functionalities (Fig. 1A). Dimerisation and 
multimerisation are mediated by domains CK and D3, respectively. The central A domain 
triplet is pivotal for adhesion and clotting, featuring binding sites for collagen (A1, A3) and 
glycoprotein Ib (GPIb, A3), and the ADAMTS13 cleavage site (A2). A1 and A3 have been 
shown by X-ray crystallography (12, 13) and A2 by homology modeling to adopt a Rossman 
α/β-fold (14). The ADAMTS13 cleavage site in A2 appears to be buried, suggesting that 
forces in stretched VWF multimers induce unfolding and exposure (15).  
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We here reveal the unfolding and activation mechanism of A2 for ADAMTS13 cleavage 
under force by molecular simulations. By applying force distribution analysis, a method 
previously introduced by our group,(16) we reveal how the atypical Rossman fold topology of 
the VWF A2 domain senses mechanical force by selectively exposing and activating the 
ADAMTS13 cleavage site. Furthermore, we predict and analyze the impact of mutations 
stabilizing the A2 domain by introducing a disulfide bond into VWF A2, in analogy to A1 
and A3. We demonstrate this mutant VWF to be resistant against ADAMTS13 in vitro. Our 
results clearly show VWF A2 domain unfolding as a response to shear stress to be the 
essential event in VWF size regulation.  
Results and Discussion 
Homology modeling of the VWF A2 domain 
To reveal the molecular process of enforced unfolding and activation of A2 at atomic detail, a 
homology model including residues 1488 to 1676 of human VWF was created (Fig. 1B). The 
model fully includes the very terminal sequences of A2, and thereby the site of mutagenesis 
for introducing a disulfide bond (see below). It is therefore more comprehensive but otherwise 
highly similar to a previous homology model that covers only the VWF residues 1496 to 1669 
(14). The multiple sequence alignment and ProSA 2003 (17) results are shown in the 
Supporting Information. The model was subjected to equilibrium Molecular Dynamics (MD) 
simulations. Within the 30 ns simulation time for each of the three independent trajectories 
the structures converged fast to a backbone root mean square deviation (rmsd) between 0.2 
and 0.25 nm (Supporting Information Fig. S3). The agreement with the previous model and 
the overall high stability indicate the quality of this A2 model and its appropriateness for the 
subsequent studies. 
The secondary structure elements of VWF A2 are organized in the typical Rossman fold as 
follows (Fig. 1C): β1 L1497 to E1504), α1 (E1511 to Q1526), β2 (I1535 to Y1542), β3 
(V1546 to P1551), α2 (D1560 to R1566), α3 (T1578 to D1587), β4 (P1601 to T1608), α4 
(R1618 to G1621), β5 (Q1624 to V1630), α5 (Q1635 to R1641), β6 (P1648 to I1651), α6 
(F1654 to C1670). The ADAMTS13 cleavage site Y1605—M1606 is located on strand β4 in 
the protein core, buried on all sides by the surrounding helices and strands, and thus 
inaccessible for ADAMTS13 in this conformation. 
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Force induced unfolding of the A2 domain 
In vivo, the size of VWF multimers is regulated by ADAMTS13 in a shear flow dependent 
manner. The shear flow elongates the VWF and results in a tensile force propagating 
throughout all VWF domains including A2 in the stretched protein (6, 7). We examined the 
effect of tensile stress on the VWF A2 conformation by force-probe MD simulations. The 
effective force in an elongated VWF multimer was accounted for by subjecting the termini of 
A2 to a pulling force in opposite directions. The resulting force profiles for three independent 
simulations are shown in Fig. 2. The initial conformation (snapshot 1, Fig. 2) is stepwise 
unfolded. Starting from the C terminus the secondary structure elements are sequentially 
peeled-off, namely of α6, β6, and α5 to yield a first intermediate (snapshot 3, Fig. 2), 
followed by β5 and α4 leading to exposure of the cleavage site (snapshot 4, Fig. 2). Overall, 
inter-β-strand interactions show higher mechanical resistance than interactions involving 
helices. A short movie in the Supporting Information illustrates the sequential unfolding of 
VWF A2 under force. 
Structural characterization and force distribution analysis of the VWF A domain 
The design of VWF A2 apparently is tailored for its force-regulated function. The stable 
N terminal β1-strand is locked to the center of the protein keeping the protein core including 
the cleavage site largely intact, while the C terminal structural elements, being more 
responsive to the external force, are pulled out step by step until the cleavage site is accessible. 
This distinct response of the two halves of the domain is determined by the underlying 
topology of the VWF A-type domains. The C terminal part of the A2 domain represents a 
classical Rossman fold with the characteristic sequential order of the secondary structure 
elements β4–α4–β5–α5–β6–α6, bridging each strand in the parallel β-sheet alignment with 
an α-helix. The sequential arrangement results in the stepwise unfolding under force 
described in the previous section. In contrast, the modified Rossman fold of the N terminal 
half of the A2 domain prevents sequential unfolding. Here, β-strands are swapped such that 
β1, the strand directly subjected to the external force, is tightly embedded in the protein core, 
so as to form rupture-resistant interactions to adjacent strands β2 and β4. We further validated 
the key role of this particular ‘knotted’ Rossman topology for the mechanical response of A2 
by force distribution analysis (FDA). FDA allows to reveal the distribution of internal strain 
within a structure subjected to an external pulling force by monitoring changes in pair wise 
atomic forces, denoted ΔF (see Methods), between a strained and relaxed state of a protein, as 
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described before (16). We determined the strain distribution in an early unfolding 
intermediate (Fig. 2, snapshot 2) from simulations at constant forces of 150 pN and 16 pN for 
the strained and relaxed state, respectively, applied to the termini of A2. This intermediate, in 
which the mechanically labile helix α6 is already unraveled, is sufficiently robust to not show 
major conformational rearrangements at the moderate external force of 150 pN during 20 
independent 30 ns simulations, as required for convergence of internal forces by FDA 
(Supplementary Fig. S4).  
For the early unfolding intermediate, the tensile force mainly propagates through the β sheets 
of the domain (Fig. 3A), following a direct path between the two termini. Force distributes 
from the most C terminal strand upstream along the sequence via strands β5 and β4 to the 
very center of the structure, and therewith to strand β1 that now guides this force out of the 
domain towards the N terminus. The strand β1 virtually shields the structure formed by the 
elements β1–α1–β2–β3–α2–α3 from force induced unfolding, as a direct results of the 
unconventional Rossman fold.  
Taking a look at inter side chain forces, this is forces that pairs of side chains exert on each 
other (see Methods), reveals another interesting feature of the stress propagation in the A2 
domain. The cleavage site residue Y1605 is the topological middle point of the domain. 
Pulling force applied at the termini puts Y1605 under very high strain, mainly created by the 
side chains of neighboring residues located in the central β strands (Fig. 3A,B, and C). In 
particular, interactions of Y1605 to V1499, F1501, and V1524 appear to be of importance, as 
they involve residues located upstream from the cleavage site, and thus remain intact also 
after further unfolding, i.e. in the intermediate that serves as substrate for ADAMTS13. To 
test directly, if the A2 unfolding intermediate is selectively stress-activated at the 
Y1605/M1606 backbone proteolysis site, we performed additional FDA for the cleavage-
ready intermediate (Fig. 2, snapshot 4), as above by constant force simulations of the strained 
and relaxed state, again both stable against unfolding at the time scales of the simulations 
(Supplementary Fig. S4). Supporting our previous observation, we found high pair wise 
forces between residues Y1605 and M1606 (Fig. 4D and E). We propose that in addition to 
mere exposure to ADAMTS13, the Y1605-M1606 proteolytic site in the VWF A2 unfolding 
intermediate is selectively tensed due to an optimized force distribution, resulting in a 
weakened peptide bond mechanically activated for cleavage.  
7 
In vitro mutagenesis and electrophoretic analysis 
Our unfolding simulations suggest A2 to be activated for ADAMTS13 cleavage under high 
shear flow conditions by exposing the cleavage site after partial unfolding of the C-terminal 
domain. A1 and A3 have highly similar amino acid sequences and three-dimensional 
structures, and thus would be expected to unfold along a similar mechanism. Examination of 
the 3D structures of the VWF A domains shows the existence of disulfide linkages between 
the termini of the A1 and A3 domains, respectively, but not for the A2 domain. A multiple 
sequence alignment (Fig. 4A and Supporting Information Fig. S1) shows both A1 and A3 to 
feature two cysteine residues each at their N and C termini, respectively, allowing the 
formation of disulfide bridges, rendering A1 and A3 insensitive against tensile stress in VWF 
under shear. A2 has only two vicinal cysteine residues at its C terminus (Fig. 4B and 
Supporting Information Fig. S1), which makes this domain mechano-responsive. Thus, the 
cysteine hooks render A1 and A3 force-resistant and potent for specific interactions with 
collagen and GPIb as essential for VWF adhesion and aggregation, while allowing the 
selective force-induced unfolding of only the A2 domain for cleavage by ADAMTS13.  
These structural and functional insights on the A domains allow us to design a VWF variant 
resistant against ADAMTS13. We introduced a cysteine at position N1493 to allow disulfide 
bond formation with residue C1669 at the A2 C-terminus in analogy to A1 and A3. C1670 
was changed to serine to generate maximal homology of A2 with A1 and A3 and to avoid the 
possibility of alternate disulfide bonding at the A2 carboxy terminal. A model of the mutant 
A2 domain was subjected to MD simulations to test the feasibility of disulfide bond formation 
and the domain’s structural integrity upon mutation (Supporting Information Fig. S3B).  
To confirm the generation of an artificially introduced A2 disulfide bond in vitro, we 
subjected A2 mutant full length recombinant VWF to multimer analysis in comparison to wild 
type VWF. Mutant VWF migrated faster than wild type VWF suggesting a more compact 
structure with higher electrophoretic mobility. In contrast, removing the disulfide bridges in 
the A1 (C1272S and D1459C) or A3 (C1686S and S1873S) towards an open structure as in 
wild type A2 resulted in a decrease of the electrophoretic mobility, both in presence (fl) and 
absence of A2 (delA2), respectively (Fig. 5A and Supporting Information Fig. S5). These 
results supported our assumption of the generation of a cysteine-bridge connection of the A2 
N and C terminus analogous to A1 and A3. We then exposed A2 domain mutant and wild 
type VWF to ADAMTS13 and monitored proteolysis by multimer analysis. We could show 
that, in contrast to wild type VWF, ADAMTS13 proteolysis of A2 domain mutant VWF was 
completely absent, similar as in A2 domain deleted VWF (Fig. 5B). This was further 
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confirmed by reduction of cysteine bonds by β-mercaptoethanol to exclude the possibility that 
the A2 domain mutant was actually proteolysed but just held together by the created cysteine 
bonds (Fig. 5C). Opening the disulfide bond of the A1 and A3 domain by mutagenesis in A2 
domain deleted VWF did not result in proteolytic susceptibility of the respective domains, 
indicating that the homology of A1 and A3 to A2 is too low for substrate recognition by 
ADAMTS13 (Fig. 5B). 
Conclusions 
We here show by simulations and in vitro mutagenesis how force-induced partial unfolding is 
required for ADAMTS13 mediated cleavage of VWF A2. The unfolding and activation 
mechanism of A2 can be abolished by a single mutation, N1669C, in analogy to the 
mechanism that presumably protects A1 and A3 from unfolding and loss of function. We find 
the C-terminal part of VWF A2 to be unraveled under force, suggesting ADAMTS13 to 
primarily recognize this partially unfolded domain rather than the native state of A2. This is in 
excellent agreement with recent in vitro studies on the interaction of VWF A2 with 
ADAMTS13 (18, 19). VWF A2 mutations previously identified to cause von Willebrand 
disease type IIA due to an increased susceptibility to ADAMTS13 (20) cleavage can now on 
the basis of our model be rationalized. They can be expected to involve destabilization of the 
overall A2 structure by forcing charged groups into regions of hydrophobic packing (I1628T 
and G1629E), perturbing β-turn formation between the VWF A2 secondary structure 
elements β5 and α5 (G1631D), or by destabilizing A2 due to a drastic increase in spatial 
demand of the side chain (G1609R). Structural destabilization in turn facilitates A2 unfolding 
and cleavage site exposure to ADAMTS13. 
The mechanical unfolding intermediates of the VWF A2 domain observed here and not a 
static intact equilibrium state from modeling or X-ray crystallography represent the substrate 
of ADAMTS13. These dynamics of the A2 structure during unfolding are prerequisite to 
explore the structural and functional determinants of A2 recognition by ADAMTS13 and 
therewith also to design inhibitors of the enzyme’s proteolytic activity, as potential drugs for 
von Willebrand disease that result from enhanced VWF cleavage in blood. 
The force-sensoring mechanism of the A2 domain provides an intriguing explanation for the 
size regulation of ULVWF: Larger multimers involve higher pulling forces and therefore 
higher unfolding rates at a given shear flow. As a result, larger VWF is cleaved more readily. 
The forces required for the exposure of the cleavage site in A2 as observed here (~500pN) can 
be expected to be significantly larger than those inducing unfolding in in vivo conditions due 
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to the short nanosecond time scale of the simulations (21). Under physiological conditions, 
cleavage shall only occur for the upper limit of VWF multimer sizes, and thus under flow 
conditions which lead to tensile forces beyond the average 5-10pN estimated for average sizes 
(6) (A Alexander-Katz, personal communication, 2009).  
While the C terminal part of the A2 domain follows a highly conserved unfolding pattern if 
subjected to tensile stress, the N terminal ‘knotted’ Rossman fold remains completely intact 
even under high forces. We hypothesize the second important function of A2, the proposed 
inhibition of the A1 GPIb interaction (22), that mediates the binding of VWF to platelets, to 
be located at this force resistant part of the domain. Thereby, as a consequence of the two 
distinct Rossman topologies within the A2 domain, size regulation of VWF by ADAMTS13 
does not affect platelet interaction. As a second consequence of the unconventional Rossman 
fold, we find strain to internally propagate selectively to the ADAMTS13 cleavage site, 
bringing the peptide bond under tension. We hypothesize the specific force-activation to 
affect the catalytic function of ADAMTS13, as a direct impact of the A2 mechanics on the 
A2-ADAMTS13 biochemistry, similar to what has been shown for disulfide bond cleavage by 
DTT and thioredoxin (23, 24). 
We here assumed the stretching force in VWF to propagate to A2 primarily via the covalent 
inter-domain linkages to adjacent A1 and A3. A full A1-A2-A3 structure is needed to re-
examine the unfolding mechanism taking inter-domain interactions into account, as a next 
important step towards deciphering the molecular details of VWF mechanical response. 
Another example for a Rossman fold in which the termini are locked together by a disulfide 
bond is the VWF type A domain of human capillary morphogenesis protein 2, interestingly 
again a collagen-binding adhesion protein (25). To what extent nature has made use of the 
Rossman fold as a module that can be reversibly switched into a force-resistant state remains 
to be seen. 
Methods 
Homology modeling and in-silico mutation 
The sequences of the VWF A domains have a residue identity of 20 to 25 %. Based on 
multiple sequence alignments and structural alignments we created a homology model of the 
VWF A2 domain (residues 1488 to 1676 of human VWF) and the mutant A2 domain 
(N1493C and C1670S) from a human VWF A1 X-ray structure (PDB: 1AUQ).  
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The search for similar sequences was performed in two steps: a fast search with a generalized 
Fasta methodology and an evaluation based on E-values and Z-scores (26). The structural 
model comprised residues 1488 to 1676 of human VWF, and therefore a longer sequence than 
the one used by (14). Finally, pdb-structures (1AUQ, 1ATZ, 1IJB, 1U0O, 2ADF, 1SHU, 
1PT6) were selected and subjected to a structural alignment. The resulting sequence 
alignment is shown in the Supplementary Information. 20 homology models were created 
from 20 randomized starting configurations, based on the VWF A1 domain (1AUQ). 
Structures were evaluated on the basis of energies from the Amber99 force field as 
implemented in MOE. Homology modeling was performed using the molecular operation 
environment MOE (2007.9, Chemical Computing Group CCG).  
Based on the model of the A2 domain, the A2 double mutant N1493C/C1670S was generated. 
A disulfide bridge was introduced between the termini by the N1493C mutation enabling a 
link between C1493 and C1669. To maintain a constant content of cysteine residues, known 
to be beneficial for protein expression (see below), a second mutation C1670S was introduced. 
The models were validated by molecular dynamics (MD) simulations. 
The coordinates of the models are available in PDB format as Supporting Information or upon 
request from the authors. 
Molecular dynamics simulation 
All simulations and part of the analysis were carried out with the Gromacs suite of programs 
(version 3.3.1) (27, 28). The OPLS all atom force field was used for the protein (29, 30). The 
proteins were solvated in dodecahedric boxes with at least 7,500 TIP4p water molecules (31), 
and periodic boundary conditions were applied. The typical protonation states at pH 7 were 
chosen for ionizable groups of the peptide. The necessary amount of counter-ions (Cl- and 
Na+) was added to ensure a neutral system. Prior to free MD simulations, steepest descent 
energy minimizations and position restrained MD simulations with heavy atom positions 
restrained with a harmonic potential using a spring constant of 1000 kJ/mol·nm2 (100 ps) were 
performed. Temperature (300 K) and pressure (1 bar) were coupled to a Nosé-Hoover 
thermostat (32, 33) and a Parrinello-Rahman barostat (34, 35), using time constants of 0.1 ps 
and 1 ps, respectively. Non-bonded interactions were considered within a cut-off of 1 nm, and 
long-range electrostatic interactions were calculated using the Particle-Mesh-Ewald algorithm 
(36, 37). Constraints were applied by the Lincs algorithm (38). A time step of 2 fs was used 
for integration. The wild type and mutant A2 models were simulated three times each for 
30 ns and with different seeds for the initial velocity generation. Three independent force-
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probe MD simulations were performed on a truncated VWF A2 model (residues 1492 to 
1670), each ~26 ns in length. Harmonic springs with spring constants of 500 kJ/(mol nm²) 
were moved away from each other with a velocity of 1.25 nm/ns. To restrict the system size 
along the pulling direction, after partial unfolding the residues 1636 to 1670 of A2 were 
removed, water was added to the system, and the force-probe MD simulations were continued.  
For FDA, a starting system was taken from a snapshot of the unfolding trajectory. Already 
unfolded parts were removed and a system containing residues 1492 to 1655 was used further 
on. Constant force of 16 and 150 pN, respectively, for the relaxed and stretched state, was 
applied in opposing direction to both termini. Each of the two systems was equilibrated under 
the respective constant force for 20 ns. For both systems, the heavy atom RMSD to the 
starting structure remained below 0.35 nm for both pulling forces, indicating that the system 
is able to bear the mechanical stress within this time scale without rupture. In the following, 
20 simulations for the folded and 10 simulation for the unfolded state were performed for 30 
ns each, starting with different random velocities. 
We used the FDA code (16) for Gromacs 4.0 (39) to write out forces Fij between each atom 
pair i and j. Forces were averaged over the total simulation time of 600 and 300 ns per system, 
respectivley, sufficient to obtain converged averages. Changes in forces, ΔF, were then 
obtained as the difference in pair wise forces between the systems pulled with 16 and 150 pN. 
To remove outliers, i.e. some large solvent exposed side chains showing a high ΔF due to 
insufficient conformational sampling, we normalized forces with the standard error between 
individual trajectories as described before (16). Changes in normalized force are denoted Δf. 
Residue wise forces resuvF  were obtained by summing up forces Fij for all pairs of atoms i and j 
in residues u and v, where atom i and atom j must not be part of the same residue; 
normalization was done as for inter atomic forces. The absolute sum ∑ Δ=Δ
v
res
uv
res
u fF  reflects 
the changes in strain acting on a single residue and was used to color code force distribution 
onto the protein backbone. Strain along the backbone was measured as the sum of all bonded 
interactions (angles + dihedrals) between adjacent residue pairs. Our MD simulations use 
LINCS to constrain bond length, and thus no forces for bonds could be calculated. As a result 
changes in backbone forces indicate strain between two residues, but the values are not 
physically correct forces. Pymol (http://www.pymol.org) (40), VMD 
(http://www.ks.uiuc.edu/Research/vmd/) (41) and POV-Ray (http://www.povray.org) were 
used for visualization. 
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VWF engineering and analysis 
By in vitro mutagenesis of full length VWF we exchanged N1493 at the N terminal site to 
cysteine and C1670, one of two neighboring cysteines at the C terminal site of the A2 domain, 
to serine to allow creation of a cysteine bond in the A2 domain. In additional mutagenesis 
experiments we also eliminated the existing disulfide bonds in the A1 (C1271S/D1459C) and 
A3 domains (C1686S/S1873C). In vitro mutagenesis of full length VWF cDNA in the 
mammalian expression vector pcDNA 3.1 by means of the quick change mutagenesis kit 
(Stratagene) using primers of 41-46 bp in length harboring the particular base exchange, 
transfer of the cDNA transfection of 293 cells by means of liposomal transfer, cell culture 
conditions, harvesting and preparing of recombinant VWF and its proteolysis by ADAMTS13 
was performed as described previously (20). ADAMTS13-proteolyzed mutant and wild type 
VWF were also analyzed by polyacrylamide gel electrophoresis under reducing conditions 
(42). 
VWF phenotypic characterization by VWF multimer analysis recorded by digital photo 
imaging was according to previously published protocols (43-45).  
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Fig. 1. (A) Schematic domain organization of the VWF with collagen binding sites (CB) in domains A1 and A3, 
a glycoprotein Ib (GPIb) binding site in A3, and the ADAMTS13 cleavage site (CS) in A2. (B) Homology model 
of A2 shown as cartoon, the cleavage site is highlighted in green. (C) Secondary structure organization, β and α 
denote β-strand and α-helix, respectively. (D) The schematic sketch of the spatial secondary structure orientation 
shows the classical Rossman-fold of the C terminal half of the A2 domain with CS (green marker) while the N 
terminal half shows a ‘knotted’ Rossman fold with significantly higher stability under force. 
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Fig. 2. The force profiles for three independent force-probe MD simulations are shown. After extending the 
protein chain to 15 nm, the simulations were continued with the unfolded C terminal part (sequence numbers 
1636 and higher) being cut off. Selected snapshots are shown as cartoon; the cleavage site is shown in green; the 
fully unfolded C-terminal fragments in 2, 3, and 4 are omitted for clarity. 
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Fig. 3. Force distribution analysis (FDA) of a ‘folded’ state (A, cf. snapshot 2 in Fig. 2) and a partially unfolded 
state (D, cf. snapshot 4 in Fig. 2) of the A2 domain: (A) Cartoon representation of an A2 folded state. Changes in 
pair wise forces, Δf, are color coded onto the protein structure. Colors range from blue for Δf=0 to red for high Δf. 
The external pulling force is mainly distributed along a direct path between the termini, bypassing helices α1 to 
α4 that are not under strain. Interestingly force propagation involves helix α5, thereby ensuring its early 
unraveling in the unfolding process. (B) Strain along the backbone of the folded structure. The cleavage site 
turns out to be under high strain, likely supporting cleavage. Strain is measured in terms of changes in bonded 
interactions between residue pairs. Please note that these values reflect strain at a certain position, but are not 
physically correct forces (see Methods). (C) Strain induced on the cleavage site residue Y1605 by side chain 
interactions. The plot shows changes in side chain forces ΔFres for Y1605, standard errors are plotted as whiskers. 
(D) Cartoon representation of the partially unfolded state, colored after backbone strain; color-coding as in A. 
Strain is measured in terms of changes in bonded interactions between residue pairs. Again, we find the cleavage 
site to be under high strain. Please note that on the C-terminal side, large part of the strain is taken up by non 
bonded interactions, as reflected by relatively low changes in backbone forces. (E) Strain along the backbone of 
the partially unfolded structure. (F) Even in the partially unfolded state, relatively high strain is induced on the 
cleavage site residue Y1605 by side chain interactions. The plot shows changes in side chain forces ΔFres for 
Y1605. In the unfolded state standard errors, plotted as whiskers, are relatively large due to the high flexibility of 
the now solvent exposed side chains. 
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Fig. 4. Comparison of the VWF A-type domains: (A) Multiple sequence alignment of the A-type domains. Only 
the N and C-terminal sequences are shown (see Supplementary Fig. S1 for the full alignment), cysteine residues 
are highlighted and disulfide bonds shown as brackets. (B) Structural superposition of A1 and A2. The A1 
domain (blue ribbons and blue carbon atoms) is locked by a disulfide bond between the termini, while the A2 
domain (orange ribbons and green atoms) lacks this feature. The exchange of residue N1493 for cysteine would 
allow disulfide bond formation.  
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Fig. 5. The electrophoretic analysis reveals the protease-stability of delA2 and mutant A2 VWF: (A) Multimer 
analysis of full length (fl) and A2 domain deleted (delA2) mutant and wild type (wt) VWF. Downwards shifted 
bands indicate faster migration of disulfide bonded mutant A2 (symbol closed circle) and delA2 compared to fl 
wild type VWF, while mutant A1 and A3 VWF migrate slower due to a more open structure (symbol open 
circle). (B) ADAMTS13 proteolysis of full length (fl) and A2 domain deleted (delA2) mutant and wild type (wt) 
VWF. Normal proteolysis is seen in wt VWF as well as in A1 and A3 domain mutant VWF with the wild type 
A2 domain present, whereas proteolysis is absent in A2 domain mutant, and in all delA2 mutants. Open circles 
denote an open structure of the A domain, closed circles denote disulfide bonded termini. (C) Full length A2 
domain mutant in comparison to wild type (wt) VWF after ADAMTS13 treatment and reduction of disulfide 
bonds. Wild type VWF is proteolyzed completely and displays the expected two proteolytic fragments after 
reduction, whereas mutant VWF is not proteolysed.  
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 Fig. S1. Multiple sequence alignment used as basis for homology modeling.  
1AUQ: A1 domain of von Willebrand factor (Emsley J, Cruz M, Handin R, Liddington R 
(1998) J Biol Chem 273: 10396-10401). 1ATZ: Human von Willebrand factor A3 domain 
(Huizinga EG, Martijn van der Plas, R, Kroon J, Sixma JJ, Gros P (1997) Structure 5: 1147-
1156). 1IJB: The von Willebrand factor mutant (I546V) A1 domain (Fukuda K, Doggett TA, 
Bankston LA, Cruz MA, Diacovo TG, Liddington RC (2002) Structure 10: 943-950). 1U0O: 
The mouse von Willebrand Factor A1-botrocetin complex (Fukuda K, Doggett T, Laurenzi IJ, 
Liddington RC, Diacovo TG (2005) Nat Struct Mol Biol 12: 152-159). 2ADF: Crystal 
Structure and Paratope Determination of 82D6A3, an Antithrombotic Antibody Directed 
Against the von Willebrand factor A3-Domain (Staelens S, Hadders MA, Vauterin S, Platteau 
C, De Maeyer M, van Hoorelbeke K, Huizinga EG, Deckmyn H (2006) J Biol Chem 281: 
2225-2231). 2SHU: Crystal Structure of the von Willebrand factor A domain of human 
capillary morphogenesis protein 2: an anthrax toxin receptor (Lacy DB, Wigelsworth DJ, 
Scobie HM, Young JAT, Collier RJ (2004) Proc Natl Acad Sci USA 101: 6367-6372). 1PT6: 
I domain from human integrin alpha1-beta1 (Nymalm Y, Puranen JS, Nyholm TKM, Kapyla 
J, Kidron H, Airenne TT, Heino J, Slotte JP, Johnson MS, Salminen TA (2004) J Biol Chem 
279: 7962-7970). 
 
Fig. S2. Verification of the Homology Model with ProSA 2003: The energy analysis is 
smoothed with a window size of 30 aa. Characterizing the model with ProSA-Web shows a Z-
score for the raw model of -6.99, and of -8.11 for the model after 10 ns MD simulation. The 
Z-score for the structure model published by Sutherland et al. is -7.84. 
 
Fig. S3. Backbone rmsd of the wild type A2 domain monitored in three independent 30 ns 
MD simulations. Backbone rmsd of the mutant A2 (N1493C/C1670S) domain monitored in 
three independent 30 ns MD simulations. 
 
 Fig. S4. (A) Superposition of the average structures under 16 and 150 pN in the folded state 
used for FDA. Structures are averages over 600 ns, respectively. (B) Superposition of the 
average structures under 16 and 150 pN of the unfolding intermediate. Structures are averages 
over 300 ns, respectively. 
 
Fig. S5. Scan of selected lanes of the gel shown in Figure 4A: The shift of bands relative to 
the wild type VWF multimers indicates faster migration of mutA2 VWF (N1493C/C1670S) 
and slower migration of mutA3 VWF (C1686S/S1873). 
 
Dataset S1. Homology model of the A2 domain including VWF residues 1488 to 1676 in 
PDB-format. 
 
Video S1. Visualization of a VWF A2 Domain Force Probe MD Simulation: 
The N (blue sphere) and C terminus (red sphere) are pulled apart from each other, the 
secondary structure elements (red: helices; yellow: strands) are stepwise peeled of until the 
Tyr1605—Met1606 cleavage site (green) is uncovered. A part of the extended and unfolded C 
terminus is removed in order to save computing time. [xvid4 encoded, AVI container] 
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